Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
777 Scudders Mill Road, Plainsboro, NJ, 08536, US
Aim to deliver transformative therapies to patients worldwide.
By: Charlie Sternberg
Breyanzi is now approved by the FDA for five cancer types.
Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.
Strengthens and diversifies its cell therapy portfolio.
The new company will focus on developing therapies for autoimmune diseases that address significant unmet needs of patients.
Dr. Cristian Massacesi will oversee the company’s early-stage and late-stage product development across all therapeutic areas.
Generic erosion for Revlimid and foreign exchange impacts results, partially offset by Opdivo and Eliquis sales and new product portfolio.
By: Kristin Brooks
Revenue growth in the quarter primarily driven by Celgene acquisition
Inclusion of additional cell lines triggers $6 million payment from BMS
Dr. Car spent 25 years at Bristol-Myers Squibb and its legacy companies
Bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo aims to treat patients with untreated advanced melanoma
By: Cassandra Gervolino
Eliquis, Opdivo sales offset decline in established brands
Transaction will create a leading specialty biopharma company in the areas of cancer, inflammatory and immunologic disease and cardiovascular disease
Eliquis and Opdivo sales help offset declines for established products
Eliquis and Opdivo sales reach $1.5 billion in the quarter
For the first IND to the FDA under Bristol-Myers Squibb collaboration
By: Betsy Louda
Eliquis and Opdivo sales drive growth in the quarter
Growth driven by Opdivo, Eliquis
Opdivo sales drive double-digit growth
Opdivo drives growth in the quarter
Opdivo, Eliquis, and Hep C franchise drives growth in the quarter
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
